Gastric cancer(GC) is a highly heterogenic disease,and it is the second leading cause of cancer death in the world.Common chemotherapies are not very effective for GC,which often presents as an advanced or metastatic ...Gastric cancer(GC) is a highly heterogenic disease,and it is the second leading cause of cancer death in the world.Common chemotherapies are not very effective for GC,which often presents as an advanced or metastatic disease at diagnosis.Treatment options are limited,and the prognosis for advanced GCs is poor.The landscape of genomic alterations in GCs has recently been characterized by several international cancer genome programs,including studies that focused exclusively on GCs in Asians.These studies identified major recurrent driver mutations and provided new insights into the mutational heterogeneity and genetic profiles of GCs.An analysis of gene expression data by the Asian Cancer Research Group(ACRG) further uncovered four distinct molecular subtypes with well-defined clinical features and their intersections with actionable genetic alterations to which targeted therapeutic agents are either already available or under clinical development.In this article,we review the ACRG GC project.We also discuss the implications of the genetic and molecular findings from various GC genomic studies with respect to developing more precise diagnoses and treatment approaches for GCs.展开更多
Gastric cancer is one of the most common malignancies with poor prognosis.The use of organoids to simulate gastric cancer has rapidly developed over the past several years.Patient-derived gastric cancer organoids serv...Gastric cancer is one of the most common malignancies with poor prognosis.The use of organoids to simulate gastric cancer has rapidly developed over the past several years.Patient-derived gastric cancer organoids serve as in vitro models that closely mimics donor characteristics,ofering new opportunities for both basic and applied research.The“Human Gastric Cancer Organoid”is part of a series of guidelines for human gastric cancer organoids in China,jointly drafted by experts from the Chinese Society for Cell Biology and its branches,and initially released on October 29,2024.This standard outlines terminology,technical requirements,assessment protocols,and applies to production,evaluation procedures,and quality control for human gastric cancer organoids.The publication of this guideline aims to assist institutions in endorsing,establishing,and applying best practices,advancing the international standardiza-tion of human gastric cancer organoids for clinical development and therapeutic application.展开更多
Organoid technology provides a transformative approach to understand human physiology and pathology,offering valuable insights for scientific research and therapeutic development.Human gastric organoids,in particular,...Organoid technology provides a transformative approach to understand human physiology and pathology,offering valuable insights for scientific research and therapeutic development.Human gastric organoids,in particular,have gained significant interest for applications in disease modeling,drug discovery,and studies of tissue regeneration and homeostasis.However,the lack of standardized quality control has limited their extensive clinical applications.The"Human Gastric Organoids"is part of a series of guidelines for human gastric organoids in China,which establishes comprehensive standards on terminology,technical specifications,testing methods,inspection rules,usage instruc-tions,labeling,transportation,and storage,developed by experts from the Chinese Society for Cell Biology and its branch societies.Released on October 29,2024,this guideline aims to establish standardized protocols,enhance insti-tutional practices,and promote international standardization for clinical and research applications of human gastric organoids.展开更多
Organoids have attracted great interest for disease modelling,drug discovery and development,and tissue growth and homeostasis investigations.However,lack of standards for quality control has become a prominent obstac...Organoids have attracted great interest for disease modelling,drug discovery and development,and tissue growth and homeostasis investigations.However,lack of standards for quality control has become a prominent obstacle to limit their translation into clinic and other applications.“Human intestinal organoids”is the first guideline on human intestinal organoids in China,jointly drafted and agreed by the experts from the Chinese Society for Cell Biology and its branch society:the Chinese Society for Stem Cell Research.This standard specifies terms and definitions,technical requirements,test methods,inspection rules for human intestinal organoids,which is applicable to quality control during the process of manufacturing and testing of human intestinal organoids.It was originally released by the Chinese Society for Cell Biology on 24 September 2022.We hope that the publication of this standard will guide institutional establishment,acceptance and execution of proper practical protocols and accelerate the international standardization of human intestinal organoids for applications.展开更多
Intestinal cancer is one of the most frequent and lethal types of cancer.Modeling intestinal cancer using organoids has emerged in the last decade.Human intestinal cancer organoids are physiologically relevant in vitr...Intestinal cancer is one of the most frequent and lethal types of cancer.Modeling intestinal cancer using organoids has emerged in the last decade.Human intestinal cancer organoids are physiologically relevant in vitro models,which provides an unprecedented opportunity for fundamental and applied research in colorectal cancer.“Human intestinal cancer organoids”is the first set of guidelines on human intestinal organoids in China,jointly drafted and agreed by the experts from the Chinese Society for Cell Biology and its branch society:the Chinese Society for Stem Cell Research.This standard specifies terms and definitions,technical requirements,test methods for human intestinal cancer organoids,which apply to the production and quality control during the process of manufacturing and testing of human intestinal cancer organoids.It was released by the Chinese Society for Cell Biology on 24 September 2022.We hope that the publication of this standard will guide institutional establishment,acceptance and execution of proper practocal protocols,and accelerate the international standardization of human intestinal cancer organoids for clinical development and therapeutic applications.展开更多
Gastric cancer is one of the most common malignancies with poor prognosis.The use of organoids to simulate gastric cancer has rapidly developed over the past several years.Patient-derived gastric cancer organoids serv...Gastric cancer is one of the most common malignancies with poor prognosis.The use of organoids to simulate gastric cancer has rapidly developed over the past several years.Patient-derived gastric cancer organoids serve as in vitro models that closely mimics donor characteristics,offering new opportunities for both basic and applied research.The“Human Gastric Cancer Organoid”is part of a series of guidelines for human gastric cancer organoids in China,jointly drafted by experts from the Chinese Society for Cell Biology and its branches,and initially released on October 29,2024.This standard outlines terminology,technical requirements,assessment protocols,and applies to production,evaluation procedures,and quality control for human gastric cancer organoids.The publication of this guideline aims to assist institutions in endorsing,establishing,and applying best practices,advancing the international standardiza-tion of human gastric cancer organoids for clinical development and therapeutic application.展开更多
文摘Gastric cancer(GC) is a highly heterogenic disease,and it is the second leading cause of cancer death in the world.Common chemotherapies are not very effective for GC,which often presents as an advanced or metastatic disease at diagnosis.Treatment options are limited,and the prognosis for advanced GCs is poor.The landscape of genomic alterations in GCs has recently been characterized by several international cancer genome programs,including studies that focused exclusively on GCs in Asians.These studies identified major recurrent driver mutations and provided new insights into the mutational heterogeneity and genetic profiles of GCs.An analysis of gene expression data by the Asian Cancer Research Group(ACRG) further uncovered four distinct molecular subtypes with well-defined clinical features and their intersections with actionable genetic alterations to which targeted therapeutic agents are either already available or under clinical development.In this article,we review the ACRG GC project.We also discuss the implications of the genetic and molecular findings from various GC genomic studies with respect to developing more precise diagnoses and treatment approaches for GCs.
基金supported by grants from the National Natural Science Foun-dation of China(31988101 to Y.-G.C.,32300586 to Y.L.W.)the National Key Research and Development Program of China(2023YFA1800603 to Y.-G.C)+1 种基金Major Project of Guangzhou National Laboratory(GZNL2023A02008 to Y.L.W.)Young Talent Support Project of Guangzhou Association for Science and Technology(QT2024-019 to Y.L.W.)。
文摘Gastric cancer is one of the most common malignancies with poor prognosis.The use of organoids to simulate gastric cancer has rapidly developed over the past several years.Patient-derived gastric cancer organoids serve as in vitro models that closely mimics donor characteristics,ofering new opportunities for both basic and applied research.The“Human Gastric Cancer Organoid”is part of a series of guidelines for human gastric cancer organoids in China,jointly drafted by experts from the Chinese Society for Cell Biology and its branches,and initially released on October 29,2024.This standard outlines terminology,technical requirements,assessment protocols,and applies to production,evaluation procedures,and quality control for human gastric cancer organoids.The publication of this guideline aims to assist institutions in endorsing,establishing,and applying best practices,advancing the international standardiza-tion of human gastric cancer organoids for clinical development and therapeutic application.
基金supported by grants from the National Natural Science Foun‑dation of China(31988101 to Y.‑G.C.,32300586 to Y.L.W.)the National Key Research and Development Program of China(2023YFA1800603 to Y.‑G.C)+1 种基金Major Project of Guangzhou National Laboratory(GZNL2023A02008 to Y.L.W.)Young Talent Support Project of Guangzhou Association for Science and Technology(QT2024‑019 to Y.L.W.)。
文摘Organoid technology provides a transformative approach to understand human physiology and pathology,offering valuable insights for scientific research and therapeutic development.Human gastric organoids,in particular,have gained significant interest for applications in disease modeling,drug discovery,and studies of tissue regeneration and homeostasis.However,the lack of standardized quality control has limited their extensive clinical applications.The"Human Gastric Organoids"is part of a series of guidelines for human gastric organoids in China,which establishes comprehensive standards on terminology,technical specifications,testing methods,inspection rules,usage instruc-tions,labeling,transportation,and storage,developed by experts from the Chinese Society for Cell Biology and its branch societies.Released on October 29,2024,this guideline aims to establish standardized protocols,enhance insti-tutional practices,and promote international standardization for clinical and research applications of human gastric organoids.
基金supported by grants from the National Natural Science Foundation of China(31988101 to Y.-G.C.,82173461 To G.Q.H.)Guangdong Basic and Applied Basic Research Foundation(2021A1515111215)to Y.L.W.+2 种基金China Postdoctoral Science Foundation(2021M703230 and 2022T150653)to Y.L.W.National Key R&D Program of China(2018YFA0108400)to T.B.Z.the Strategic Priority Research Program of the Chinese Academy of Sciences(XDA16040501)to A.J.M..
文摘Organoids have attracted great interest for disease modelling,drug discovery and development,and tissue growth and homeostasis investigations.However,lack of standards for quality control has become a prominent obstacle to limit their translation into clinic and other applications.“Human intestinal organoids”is the first guideline on human intestinal organoids in China,jointly drafted and agreed by the experts from the Chinese Society for Cell Biology and its branch society:the Chinese Society for Stem Cell Research.This standard specifies terms and definitions,technical requirements,test methods,inspection rules for human intestinal organoids,which is applicable to quality control during the process of manufacturing and testing of human intestinal organoids.It was originally released by the Chinese Society for Cell Biology on 24 September 2022.We hope that the publication of this standard will guide institutional establishment,acceptance and execution of proper practical protocols and accelerate the international standardization of human intestinal organoids for applications.
基金supported by grants from the National Natural Science Foundation of China(31988101 to Y.-G.C.,82173461 To G.Q.H.)Guangdong Basic and Applied Basic Research Foundation(2021A1515111215)to Y.L.W.+2 种基金China Postdoctoral Science Foundation(2021M703230 and 2022T150653)to Y.L.W.National Key R&D Program of China(2018YFA0108400)to T.B.Z.the Strategic Priority Research Program of the Chinese Academy of Sciences(XDA16040501)to A.J.M..
文摘Intestinal cancer is one of the most frequent and lethal types of cancer.Modeling intestinal cancer using organoids has emerged in the last decade.Human intestinal cancer organoids are physiologically relevant in vitro models,which provides an unprecedented opportunity for fundamental and applied research in colorectal cancer.“Human intestinal cancer organoids”is the first set of guidelines on human intestinal organoids in China,jointly drafted and agreed by the experts from the Chinese Society for Cell Biology and its branch society:the Chinese Society for Stem Cell Research.This standard specifies terms and definitions,technical requirements,test methods for human intestinal cancer organoids,which apply to the production and quality control during the process of manufacturing and testing of human intestinal cancer organoids.It was released by the Chinese Society for Cell Biology on 24 September 2022.We hope that the publication of this standard will guide institutional establishment,acceptance and execution of proper practocal protocols,and accelerate the international standardization of human intestinal cancer organoids for clinical development and therapeutic applications.
基金National Natural Science Foundation of China(31988101 to Y.‑G.C.,32300586 to Y.L.W.)National Key Research and Development Program of China(2023YFA1800603 to Y.‑G.C)+1 种基金Major Project of Guangzhou National Laboratory(GZNL2023A02008 to Y.L.W.)Young Talent Support Project of Guangzhou Association for Science and Technology(QT2024‑019 to Y.L.W.).
文摘Gastric cancer is one of the most common malignancies with poor prognosis.The use of organoids to simulate gastric cancer has rapidly developed over the past several years.Patient-derived gastric cancer organoids serve as in vitro models that closely mimics donor characteristics,offering new opportunities for both basic and applied research.The“Human Gastric Cancer Organoid”is part of a series of guidelines for human gastric cancer organoids in China,jointly drafted by experts from the Chinese Society for Cell Biology and its branches,and initially released on October 29,2024.This standard outlines terminology,technical requirements,assessment protocols,and applies to production,evaluation procedures,and quality control for human gastric cancer organoids.The publication of this guideline aims to assist institutions in endorsing,establishing,and applying best practices,advancing the international standardiza-tion of human gastric cancer organoids for clinical development and therapeutic application.
